Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2694254 | 1.00 | CXCR4 (0.41) | CXCR4CTSDNAMPTHRH3HDAC1 | |
| SCHEMBL2694258 | 1.00 | CXCR4 (0.41) | CXCR4CTSDNAMPTHRH3HDAC1 | |
| SCHEMBL2697476 | 1.00 | CXCR4 (0.41) | CXCR4CTSDNAMPTHRH3HDAC1 | |
| SCHEMBL2694141 | 0.93 | CXCR4 (0.41) | CXCR4CTSDNAMPTHRH3SLC2A1 | |
| SCHEMBL2694136 | 0.93 | CXCR4 (0.41) | CXCR4CTSDNAMPTHRH3SLC2A1 | |
| SCHEMBL2694832 | 0.93 | CXCR4 (0.49) | CXCR4CTSDNAMPTHRH3HDAC1 | |
| SCHEMBL1795085 | 0.93 | CXCR4 (0.49) | CXCR4CTSDNAMPTHRH3HDAC1 | |
| SCHEMBL1794518 | 0.93 | CXCR4 (0.49) | CXCR4CTSDNAMPTHRH3HDAC1 | |
| SCHEMBL1793856 | 0.93 | CXCR4 (0.49) | CXCR4CTSDNAMPTHRH3HDAC1 | |
| SCHEMBL1794701 | 0.92 | CXCR4 (0.49) | CXCR4CTSDNAMPTHRH3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8168783-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | CXCR4, CXCL12, CXCR3 | CXCR4 1/4885CTSD 3136/4885NAMPT 723/4885 |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR3, CXCR1 | CXCR4 1/4885CTSD 3050/4885NAMPT 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.